Create Free Account

By creating account you will get access to hot stocks & personalised emails

Regeneron Pharmaceuticals Inc

Healthcare US REGN

710.175USD
-4.445(0.62%)

Last update at 2024-12-19T18:57:00Z

Day Range

693.00714.05
LowHigh

52 Week Range

684.80998.33
LowHigh

Fundamentals

  • Previous Close 714.62
  • Market Cap107228.60M
  • Volume527725
  • P/E Ratio29.07
  • Dividend Yield-%
  • EBITDA4424.50M
  • Revenue TTM13100.10M
  • Revenue Per Share TTM122.57
  • Gross Profit TTM 7020.00M
  • Diluted EPS TTM33.48

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 4858.80M 9325.80M 3810.40M 2429.10M 2553.50M
Minority interest - - - - -
Net income 4338.40M 8075.30M 3513.20M 2115.80M 2444.40M
Selling general administrative 2115.90M 1824.90M 1346.00M 1834.80M 1556.20M
Selling and marketing expenses - - - - -
Gross profit 10612.50M 13634.20M 7377.20M 7081.20M 6276.70M
Reconciled depreciation 341.40M 286.20M 235.90M 210.30M 148.20M
Ebit 4738.90M 8946.80M 3576.60M 1999.50M 2386.20M
Ebitda 5173.30M 9383.10M 3867.30M 2209.80M 2534.40M
Depreciation and amortization 434.40M 436.30M 290.70M 210.30M 148.20M
Non operating income net other 179.30M 436.30M 290.70M 249.50M 47.30M
Operating income 4738.90M 8946.80M 3576.60M 2209.80M 2534.40M
Other operating expenses 7178.90M 7124.90M 4920.50M 5653.60M 4176.40M
Interest expense 59.40M 57.30M 56.90M 30.20M 28.20M
Tax provision 520.40M 1250.50M 297.20M 313.30M 109.10M
Interest income 160.10M - - 88.10M 13.70M
Net interest income 100.70M -57.30000M -56.90000M -30.20000M -28.20000M
Extraordinary items - - - - 68.00M
Non recurring 255.10M - - - -
Other items - - - - -
Income tax expense 520.40M 1250.50M 297.20M 313.30M 109.10M
Total revenue 12172.90M 16071.70M 8497.10M 7863.40M 6710.80M
Total operating expenses 5618.50M 4687.40M 3800.60M 4871.40M 3742.30M
Cost of revenue 1560.40M 2437.50M 1119.90M 782.20M 434.10M
Total other income expense net 119.90M 379.00M 233.80M 219.30M 19.10M
Discontinued operations - - - - -
Net income from continuing ops 4338.40M 8075.30M 3513.20M 2115.80M 2444.40M
Net income applicable to common shares 4338.40M 8075.30M 3513.20M 2115.80M 2444.40M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 33080.20M 29214.50M 25434.80M 17163.30M 14805.20M
Intangible assets 1038.60M 915.50M - - -
Earning assets - - - - -
Other current assets 386.60M 933.00M 332.40M 1164.00M 959.30M
Total liab 7107.10M 6550.50M 6666.00M 6138.00M 3715.50M
Total stockholder equity 25973.10M 22664.00M 18768.80M 11025.30M 11089.70M
Deferred long term liab - - - - -
Other current liab 2357.90M 1992.20M 1725.30M 122.40M 781.10M
Common stock 0.10M 0.10M 0.10M 0.10M 0.10M
Capital stock 0.10M 0.10M 0.10M 0.10M 0.10M
Retained earnings 27260.30M 23306.70M 18968.30M 10893.00M 7379.80M
Other liab - 707.80M 515.30M 635.50M 889.00M
Good will - - - - -
Other assets - 747.60M 555.20M 2770.00M 913.30M
Cash 2730.00M 3105.90M 2885.60M 2193.70M 1617.80M
Cash and equivalents - - - - -
Total current liabilities 3423.40M 3849.10M 3451.00M 2806.80M 1790.90M
Current deferred revenue 458.90M 547.70M 442.00M 577.70M 591.70M
Net debt -27.10000M -404.50000M -185.90000M 502.00M -903.90000M
Short term debt - 720.00M 719.70M 1631.20M -
Short long term debt - - - - -
Short long term debt total 2702.90M 2701.40M 2699.70M 2695.70M 713.90M
Other stockholder equity -1206.40000M -404.00000M -173.40000M 102.90M 3688.70M
Property plant equipment - 3763.00M 3482.20M 3221.60M 2890.40M
Total current assets 19479.20M 22064.70M 20520.50M 12753.90M 10558.80M
Long term investments 5396.50M 6591.80M 6838.00M 3135.60M 3256.80M
Net tangible assets - 21748.50M 18768.80M 11025.30M 11089.70M
Short term investments 8114.80M 4636.40M 2809.10M 1393.30M 1596.50M
Net receivables 5667.30M 5328.70M 6036.50M 4114.70M 2672.20M
Long term debt 1982.90M 1981.40M 1980.00M 1978.50M -
Inventory 2580.50M 2401.90M 1951.30M 1916.60M 1415.50M
Accounts payable 606.60M 589.20M 564.00M 475.50M 418.10M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -80.90000M -238.80000M -26.20000M 29.30M 21.10M
Additional paid in capital - - - - -
Common stock total equity - 0.10M 0.10M 0.10M 0.10M
Preferred stock total equity - - - - -
Retained earnings total equity - 23306.70M 18968.30M 10893.00M 7379.80M
Treasury stock - - -8260.90000M -6613.30000M -739.90000M
Accumulated amortization - - - - -
Non currrent assets other 444.10M -4658.80000M 555.20M 328.90M 531.80M
Deferred long term asset charges - - - - -
Non current assets total 13601.00M 7149.80M 4914.30M 4409.40M 4246.40M
Capital lease obligations 720.00M 720.00M 719.70M 717.20M 713.90M
Long term debt total - 1981.40M 1980.00M 1978.50M 713.90M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments -4976.60000M -1937.40000M -4832.80000M 544.00M -1598.20000M
Change to liabilities - -106.00000M 745.90M 267.00M 738.50M
Total cashflows from investing activities - -3784.60000M -5384.70000M -70.60000M -2027.80000M
Net borrowings - - - 1981.90M 1981.90M
Total cash from financing activities -1790.10000M -1009.00000M -1005.80000M -1970.50000M -252.10000M
Change to operating activities - -148.60000M -240.70000M 114.90M -130.40000M
Net income 3953.60M 4338.40M 8075.30M 3513.20M 2115.80M
Change in cash -381.60000M 221.30M 690.80M 577.00M 150.10M
Begin period cash flow 3119.40M 2898.10M 2207.30M 1630.30M 1480.20M
End period cash flow 2737.80M 3119.40M 2898.10M 2207.30M 1630.30M
Total cash from operating activities 4594.00M 5014.90M 7081.30M 2618.10M 2430.00M
Issuance of capital stock 1217.10M 1519.50M 1672.30M 2575.20M 211.80M
Depreciation 421.00M 341.40M 286.20M 235.90M 210.30M
Other cashflows from investing activities - -1257.10000M - - -1598.20000M
Dividends paid - - - - -
Change to inventory -271.70000M -696.50000M -494.30000M -529.40000M -335.50000M
Change to account receivables -338.80000M 707.80M -1927.40000M -1356.10000M -473.10000M
Sale purchase of stock -2935.60000M -2528.50000M -2678.10000M -6527.60000M -463.90000M
Other cashflows from financing activities -700.60000M -445.70000M -1032.70000M 3481.90M -188.00000M
Change to netincome - 676.50M -994.00000M -895.10000M 314.20M
Capital expenditures 926.40M 590.10M 551.90M 614.60M 429.60M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - 221.30M 690.80M 577.00M 150.10M
Change in working capital -94.10000M -243.30000M -1916.50000M -1503.60000M -200.50000M
Stock based compensation 885.00M 725.00M 601.70M 432.00M 464.30M
Other non cash items 266.30M 599.80M 181.70M -135.00000M -29.30000M
Free cash flow 3667.60M 4424.80M 6529.40M 2003.50M 2000.40M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
REGN
Regeneron Pharmaceuticals Inc		 -4.445 0.62% 710.17 29.07 20.12 7.57 3.82 6.95 19.42
NVO
Novo Nordisk A/S		 -2.26 2.13% 103.70 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -1.68 1.57% 105.12 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -55.6951 12.45% 391.80 29.67 24.33 10.38 5.83 9.33 20.00
CSLLY
CSL Ltd		 -0.54 0.62% 86.46 42.45 26.95 7.05 5.80 7.85 26.51

Reports Covered

Stock Research & News

View All

Profile

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Regeneron Pharmaceuticals Inc

777 Old Saw Mill River Road, Tarrytown, NY, United States, 10591-6707

Key Executives

Name Title Year Born
Dr. Leonard S. Schleifer M.D., Ph.D. Founder, Pres, CEO & Director 1953
Dr. George D. Yancopoulos M.D., Ph.D. Scientific Founder, Pres, Chief Scientific Officer & Director 1960
Mr. Robert E. Landry Jr. Exec. VP of Fin. & CFO 1964
Mr. Joseph J. LaRosa Exec. VP, Gen. Counsel & Sec. 1959
Dr. Andrew J. Murphy Ph.D. Exec. VP of Research 1959
Mr. Daniel P. Van Plew Exec. VP and GM of Industrial Operations & Product Supply 1973
Ms. Patrice Gilooly Sr. VP of Quality Assurance & Operations NA
Mr. Christopher R. Fenimore Sr. VP, Head of Accounting & Controller 1971
Mr. Gerald Underwood Sr. VP of Technical Operations NA
Mr. Bob McCowan Sr. VP of IT & Chief Information Officer NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.

Our Company

Useful Links

Contact Us

ISO Certified Market Research

Kalkine Solutions Private Limited, authorized representative of Kalkine Pty Ltd, holds ISO 27001:2022 certification bearing Certificate No.- IC-IS-2404072

Our Company

Useful Links

Contact Us

Disclaimer

The information given by Kalkine Pty Ltd ABN34 154 808 312 (Australian Financial Services License Number 425376) on this website is general information or advice only.

It does not take into account any of your personal objectives, circumstances or needs. Choosing an investment is an important decision. If you do not feel confident making a decision based on the recommendations Kalkine has made in our reports, you should consider obtaining personal advice from an authorised adviser.

There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. Terms & Conditions have been provided for our services, please go through them and also read our Financial Services Guide.

Our website may contain information on past performance of particular investments. Past performance is not an indicator of future performance. Hypothetical returns may not reflect actual performance. Any displays of potential investment opportunities are for sample purposes only and may not actually be available to investors.

The information on the website does not constitute an offer to sell securities or a solicitation of an offer to buy securities. Our reports contain general recommendations to invest in securities.

Copyright 2024 Krish Capital Pty. Ltd. All rights reserved. No part of this website, or its content, may be reproduced in any form without our prior consent.